Heart Valve, Spine Markets To Drive Device Growth After DES – CMS Report
This article was originally published in The Gray Sheet
Percutaneous heart valve repair and replacement likely will drive the next wave of medical device industry expansion as cardiac resynchronization therapy (CRT) and drug-eluting stent innovations plateau, a CMS report speculates
You may also be interested in...
Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11
Federal law requiring agencies to weigh and document potential environmental impacts of major regulatory actions does not dictate what happens next. Neither does it provide federal agencies with authorities beyond their statutory purviews, FDA/CDER leadership says.
The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.